10-Q: Windtree Therapeutics Faces Delisting, Reports $42.8M Loss

Windtree Therapeutics reported a significant net loss of $42.8 million for the nine months ended September 30, 2025, alongside a Nasdaq delisting and substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, was $42.8 million, a substantial increase from $4.6 million in the prior year.
• The company recorded a $16.1 million impairment charge on intangible assets, primarily related to the istaroxime drug candidate.
• Windtree Therapeutics was delisted from Nasdaq on August 19, 2025, and now trades on the OTCID market.
• The SEISMiC C clinical trial for istaroxime in severe cardiogenic shock was terminated due to insufficient funding, with future development shifting to acute decompensated heart failure with a licensing partner.
• Management has launched a new corporate strategy to acquire small companies with FDA-approved products to generate revenue.
• The company has insufficient cash to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Secured a $500 million equity line of credit (ELOC) and issued new convertible notes totaling $2.35 million in October and November 2025.
• Terminated a Letter of Intent to acquire Titan Environmental Services, Inc., converting a $7.5 million advance into equity of TESI or a surviving entity.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a substantial net loss, a going concern warning, and delisting from Nasdaq. The termination of a clinical trial due to funding issues and high dilution risk contribute to a very negative outlook, despite new strategic initiatives.

Positives

• Secured a $500 million equity line of credit (ELOC) with Seven Knots, LLC, providing a potential source of future capital.
• Became the manufacturing sourcing agent for Evofem's FDA-approved product Phexxi in March 2025.
• Signed a manufacturing deal with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited in June 2025 to produce an approved product at lower cost.
• Istaroxime Phase 2b SEISMiC Extension Study showed positive topline results, improving cardiac function and blood pressure without increasing heart rate.
• Istaroxime has Fast Track designation from the U.S. FDA for acute heart failure.
• Received a $3.4 million income tax benefit for the nine months ended September 30, 2025, primarily from the reversal of deferred taxes due to the intangible asset impairment charge and an election not to capitalize R&D costs.

Negatives

• Reported a net loss of $42.8 million for the nine months ended September 30, 2025, significantly higher than the $4.6 million loss in the prior year.
• Incurred a $16.1 million impairment charge on intangible assets, mainly for the istaroxime drug candidate, reflecting a decline in fair value.
• Delisted from the Nasdaq Capital Market on August 19, 2025, and now trades on the OTCID, which may reduce liquidity and market quotations.
• The SEISMiC C clinical trial for istaroxime in severe cardiogenic shock was terminated due to the inability to secure adequate resourcing.
• Current cash and cash equivalents of $0.2 million are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Total current liabilities increased significantly to $21.9 million as of September 30, 2025, from $5.7 million at December 31, 2024.
• Incurred a $22.4 million loss on debt issuances for the nine months ended September 30, 2025.
• Terminated the Letter of Intent to acquire Titan Environmental Services, Inc., converting a $7.5 million advance into equity of TESI or a surviving entity, rather than a cash return.
• Rostafuroxin development is on hold, awaiting licensing arrangements or strategic partnerships, and requires an additional Phase 2 clinical trial.
• Significant dilution risk for shareholders due to ongoing equity and convertible debt financings.

Risks

• Inability to obtain sufficient additional capital on acceptable terms to fund continuing operations, which raises substantial doubt about the ability to continue as a going concern.
• Risks of failure in preclinical and clinical studies for product candidates.
• Difficulties in obtaining marketing approval and reimbursement for any developed drug product candidates.
• Challenges in successfully commercializing and gaining market acceptance for product candidates.
• Dependence on key personnel and the ability to recruit or retain them.
• Risks associated with protecting proprietary technology.
• Compliance with government regulations.
• Development of technological innovations by competitors.
• Risks associated with international operations, including foreign suppliers, manufacturers, and clinical sites.
• Potential impairment of intangible assets if the share price continues to decline.
• Restrictive covenants in existing Note Purchase Agreements may limit the ability to procure additional financing.
• Sales of a substantial number of common stock shares, including under the equity line of credit, could depress the market price and impair future capital raising.
• Reduced liquidity and market quotations for common stock due to delisting from Nasdaq and trading on the OTCID.
• Potential for the common stock to be deemed "penny stock," leading to more stringent trading rules and reduced trading activity.
• Increased state-level regulation for securities offerings due to delisting from Nasdaq.
• Cyber-attacks, malicious intrusion, breakdown, destruction, security incidents, data privacy violations, or other significant disruptions to internal computer and information systems.
• Economic uncertainty from inflation, interest rate fluctuations, and geopolitical instability (Russia-Ukraine, China-Taiwan, Middle East).
• Uncertainty regarding the success of the new business strategy to generate revenue through acquisitions of small companies and their FDA-approved products.

Future Outlook

Management plans to secure additional capital through public or private securities offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements and drug product collaborations. The company is pursuing a new corporate strategy to become a revenue-generating biotech company through acquisitions of small companies with FDA-approved products. Future development for istaroxime will focus on acute decompensated heart failure with licensing partner Lees Pharmaceutical (HK) Ltd., who is planning a global Phase 3 study. The company will continue to evaluate and pursue potential partnerships for its biotechnology pipeline.

Management Comments

• "We believe that istaroxime has the potential to fulfill an unmet need in early and potentially more severe cardiogenic shock."
• "Because our ability to complete this study with its intended sample size is dependent upon our ability to secure adequate resourcing for the program through financing efforts or business development activities we have decided to terminate the SEISMiC C clinical trial and pursue further development with istaroxime in the much larger market of less severe patients with acute decompensated heart failure with our licensing partner, Lees Pharmaceutical (HK) Ltd., who is planning a global phase 3 study in that indication."
• "In January 2025, we launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to seek partnership to progress its cardiovascular and oncology development pipeline."
• "We believe there is an opportunity in the market: the acquisition of small companies with FDA-approved products from the many small biotech companies that struggle to maximize their commercialization potential."

Industry Context

The company operates in the biotechnology industry, which is characterized by high capital requirements, risks of clinical trial failures, and challenges in regulatory approval and commercialization. The new corporate strategy to acquire small companies with FDA-approved products aims to capitalize on a perceived market opportunity where many small biotech companies struggle to maximize their commercialization potential, suggesting a fragmented market with acquisition targets.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Not aware of any pending legal actions that would have a material adverse effect on business and operations.
• Potentially susceptible to litigation, such as claims asserting violations of securities laws, which could be time-consuming and costly.

Related Party Transactions

• Seven Knots, LLC is a holder of the company's Series C Preferred Stock, Series D Preferred Stock, certain convertible notes payable, and is the purchaser in the $500 million ELOC Purchase Agreement.
• Former CEO, Mr. Fraser, and CMO, Dr. Simonson, participated in the First PIPE (private placement) in July 2024, purchasing Series C Preferred Stock and July 2024 Warrants.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity and convertible debt financings.
• Shareholders experience reduced liquidity and market visibility due to the delisting from Nasdaq to the OTCID market.
• Shareholders face substantial risk of investment loss due to the company's going concern doubt and precarious financial position.
• Employees may face uncertainty regarding job security and the company's long-term viability given the financial challenges and strategic shifts.
• Creditors (holders of convertible notes and other debt) are exposed to the company's financial distress and potential inability to repay obligations, although some notes have senior status or prepayment premiums.

Next Steps

• Secure additional capital through public or private securities offerings, convertible debt financings, and/or strategic transactions.
• Pursue further development with istaroxime in acute decompensated heart failure with licensing partner Lees Pharmaceutical (HK) Ltd., who is planning a global Phase 3 study.
• Seek acquisition targets for the new corporate strategy to acquire small companies with FDA-approved products.
• Continue to evaluate and pursue potential partnerships for the biotechnology pipeline.
• Advance investigational new drug enabling activities and determine the clinical development plan for the aPKCi inhibitor platform.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by a substantial net loss of $42.8 million for the nine months ended September 30, 2025, and an accumulated deficit of $889.4 million. The explicit "going concern" warning, stating insufficient cash to fund operations for the next 12 months, is a critical red flag for investors. The delisting from Nasdaq to the OTCID market significantly reduces liquidity and market visibility, further increasing investment risk. The termination of the SEISMiC C clinical trial due to lack of resources highlights ongoing funding challenges for its core biotech pipeline. While the new strategy to acquire FDA-approved products is an attempt to generate revenue, it is unproven and carries inherent execution risks, especially given the company's current financial state. The reliance on equity lines of credit and convertible notes indicates a high potential for further shareholder dilution. These factors collectively point to a highly speculative and high-risk investment, warranting a strong sell recommendation.

Keywords

Biotechnology, Pharmaceutical, Cardiogenic Shock, Acute Heart Failure, Istaroxime, SEC Filing, 10-Q, Financial Report, Nasdaq Delisting, Going Concern, Equity Line of Credit, Convertible Notes, Drug Development, Clinical Trials, SERCA2a Activators, Rostafuroxin, aPKCi Inhibitor, WINT, OTC Markets, Capital Raise, Intangible Asset Impairment, Corporate Strategy, Biotech Acquisitions